An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials

Statistics in Medicine

Volumn 34, Issue 4, 2015, Pages 541-557

  Garès, Valérie ^a,b,c   Andrieu, Sandrine ^a,c   Dupuy, Jean François ^d   Savy, Nicolas ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSTITUT DE MATHÉMATIQUES DE TOULOUSE   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Clinical trials; Hypothesis testing; Maximum weighted tests; Survival data

Indexed keywords

GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

AGED; ALZHEIMER DISEASE; BIOSTATISTICS; COMPUTER SIMULATION; GINKGO BILOBA; HUMAN; PRIMARY PREVENTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STATISTICS AND NUMERICAL DATA;

AGED; ALZHEIMER DISEASE; BIOSTATISTICS; COMPUTER SIMULATION; GINKGO BILOBA; HUMANS; PLANT EXTRACTS; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 84920446257     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6366     Document Type: Article

References (37)

1. Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. Alzheimer's Disease International: London, 2010.
2. Brookmeyer R, Gray S, Kawas C . Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998; 88(9):1337-1342.
3. Brookmeyer R. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia 2007; 3(3):186-191.
4. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer 1959; 22:719-748.
5. DeKosky ST. Ginkgo biloba for prevention of dementia: a randomized controlled trial. Journal of the American Medical Association 2008; 300(19):2253-2262.
6. Lyketsos CG. Naproxen and celecoxib do not prevent Alzheimer's disease in early results from a randomized controlled trial. Neurology 2007; 68(21):1800-1808.
7. Shumaker SA. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 2003; 289(20):2651-2662.
8. Shumaker SA. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. Journal of the American Medical Association 2004; 291(24):2947-2958.
9. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society: Series B 1972; 34:187-220.
10. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52:203-223.
11. Tarone RE, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977; 64(1):156-160.
12. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society: Series A 1972; 135:185-206.
13. Prentice RL. Linear rank tests with right censored data. Biometrika 1978; 65(1):167-179.
14. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982; 69(3):553-566.
15. Buyske S, Fagerstrom R, Ying Z. A class of weighted log-rank tests for survival data when the event is rare. Journal of the American Statistical Association 2000; 95(449):249-258.
16. Zucker DM, Lakatos E. Weighted log rank type statistics for comparing survival curves when there is a time lag in the effectiveness of treatment. Biometrika 1990; 77(4):853-864.
17. Fleming TR, Harrington DP. Counting Processes and Survival Analysis, Wiley Series in Probability and Mathematical Statistics: Applied Probability and Statistics. John Wiley & Sons Inc: New York, 1991.
18. Wu L, Gilbert PB. Flexible weighted log-rank tests optimal for detecting early and/or late survival differences. Biometrics 2002; 58(4):997-1004.
19. Wallenstein S, Berger A. Weighted logrank tests to detect a transient improvement in survivorship. Biometrics 1997; 53(2):736-744.
20. Gastwirth JL. The use of maximin efficiency robust tests in combining contingency tables and survival analysis. Journal of The American Statistical Association 1985; 80(390):381-384.
21. Zucker DM. The efficiency of a weighted log-rank test under a percent error misspecification model for the log hazard ratio. Biometrics 1992; 48(3):893-899.
22. Lee JW. Some versatile tests based on the simultaneous use of weighted log-rank statistics. Biometrics 1996; 52(2):721-725.
23. Breslow NE, Edler L, Berger J. A two-sample censored-data rank test for acceleration. Biometrics 1984; 40(4):1049-1062.
24. Self SG. An adaptive weighted log-rank test with application to cancer prevention and screening trials. Biometrics 1991; 47(3):975-986.
25. Lai TL, Ying Z. Rank regression methods for left-truncated and right-censored data. The Annals of Statistics 1991; 19(2):531-556.
26. Pecková M, Fleming TR. Adaptive test for testing the difference in survival distributions. Lifetime Data Analysis 2003; 9(3):223-238.
27. Yang S, Prentice R. Improved logrank-type tests for survival data using adaptive weights. Biometrics 2010; 66(1):30-38.
28. Fleming TR, Harrington DP, O'Sullivan M. Supremum versions of the log-rank and generalized Wilcoxon statistics. Journal of the American Statistical Association 1987; 82(397):312-320.
29. Eng KH, Kosorok MR. A sample size formula for the supremum log-rank statistic. Biometrics 2005; 61(1):86-91.
30. Kosorok MR, Lin CY. The versatility of function-indexed weighted log-rank statistics. Journal of the American Statistical Association 1999; 94(445):320-332.
31. Feng W, Wahed AS. Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies. Biometrika 2008; 95(3):695-707.
32. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurology 2012; 11(10):851-859.
33. Garès V, Andrieu S, Dupuy JF, Savy N. About the parameter of Fleming-Harrington's test in prevention randomized controlled trials 10 2014. Submitted.
34. Gill RD. Censoring and Stochastic Integrals. Mathematical Centre Tracts 124. Mathematisch Centrum: Amsterdam, 1980.
35. Halperin M, Rogot E, Gurian J, Ederer F. Sample sizes for medical trials with special reference to long-term therapy. Biometrics 1967; 21:13-24.
36. Schork MA, Remington RD. The determination of sample size in treatment-control comparisons for chronic disease studies in which noncompliance on nonadherence is a problem. Journal of Chronic Diseases 1967; 20:233-239.
37. Lakatos E, Lan KG. A comparison of sample size methods for the logrank statistic. Statistics in Medicine 1992; 11:179-191.